Archive: Health/Long-Term Care
The Food and Drug Administration recently granted fast-track approval to a new Alzheimer’s drug designed to slow the rate of cognitive decline for individuals in the early stages of the disease. The drug, which will be sold under the brand name Leqembi, was developed jointly by Eisai and Biogen – the same two companies that…
The brief’s key findings are: In the first year of the pandemic, 300,000 Americans ages 60+ died from COVID, with the oldest and least healthy at greater risk. The question here is, since those who died tended to be more vulnerable, to what extent will the survivors have lower mortality rates? The analysis estimates that…
